Bluejay Diagnostics Inc (BJDX)

$0.67 +0.01 (1.82%)
Market Cap 1.18M
Revenue (ttm) 0.00
Net Income (ttm) -7.72M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 65,773
Avg Vol 107,418
Day's Range N/A - N/A
Shares Out 1.81M
Stochastic %K 22%
Beta 0.65
Analysts Strong Buy
Price Target $32.00

Company Profile

Bluejay Diagnostics, Inc. operates as a medical diagnostics company. The company offers the Symphony platform, a technology platform comprising the Symphony analyzer that orchestrates whole blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and the Symphony Cartridge, which includes reagents and components. It also provides the ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, the compa...

Industry: Medical Devices
Sector: Healthcare
Phone: 844 327 7078
Address:
360 Massachusetts Avenue, Suite 203, Acton, United States
Mike_Rotsch
Mike_Rotsch Jan. 13 at 3:02 PM
$BJDX It's time.
0 · Reply
StockDocOne
StockDocOne Jan. 13 at 2:04 AM
$BJDX
0 · Reply
GeoArafin
GeoArafin Jan. 9 at 4:57 PM
$BJDX
0 · Reply
rombrento
rombrento Jan. 9 at 12:15 PM
$BJDX
0 · Reply
HabibiMeaux
HabibiMeaux Jan. 7 at 4:53 PM
$BJDX I come back to this ticket every couple weeks to check in on it and unless they pull some magic I can see it getting delisted. Very likely they’ll do a reverse split to comply with the price requirement but that can only work for so long
0 · Reply
JohnTrack
JohnTrack Dec. 30 at 8:33 PM
$BJDX short card https://www.rapidticker.com/news/bjdx-sec-filing-16224a
0 · Reply
JohnTrack
JohnTrack Dec. 29 at 2:59 PM
$BJDX watching if shorts cover...
0 · Reply
AllandaleCapital
AllandaleCapital Dec. 29 at 12:59 PM
$BJDX in case anyone in curious off the news this am, live short interest is 4.08% Shares: 4.06M OS / 4.06M float Price: ~0.70 Market Cap: ~$3M Cash: ~$6M (Q3 est.) Cash Runway: ~12 months November 2023 (HC Wainwright) • 2,692,308 shares @ $1.30 • 2,692,308 warrants @ $1.30 • $3.5M raised June 2024 (Aegis) • 5,368,098 shares @ $1.63 • 16,104,294 warrants @ $1.96 (300% coverage) • $8.75M raised August 2024 — Toxic Cleanup • 435,377 warrants @ $0.00 strike exercised → 6.6M shares (L1) • No cash to company (pure dilution) April 2025 — Warrant Exercise (Aegis) • 1,085,106 warrants exercised @ $3.42 • $3.71M cash in • Same strike replacement warrants reissued October 2025 — Private Placement (Rodman & Renshaw) • 2,250,000 shares @ $2.00 • 4,500,000 warrants @ $1.75 • $4.5M raised Current Overhang: • ~4.5M warrants @ $1.75 (main overhang) • 1.08M warrants @ $3.42 (exercised/reissued) • 287k warrants @ $16.30 (irrelevant at current levels) • Legacy high-strike warrants ($520, $2,896, etc.) = irrelevant
0 · Reply
JohnTrack
JohnTrack Dec. 29 at 12:30 PM
$BJDX Completion of Commercial-Scale IL-6 Antibody Produ
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Dec. 29 at 12:16 PM
$BJDX Bluejay Diagnostics Completes Commercial-Scale Production Of Polyclonal And Monoclonal Antibodies Targeting Interleukin-6, Biomarker Relevant To Inflammatory And Critical-Care Applications
0 · Reply
Latest News on BJDX
Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production

Dec 29, 2025, 7:00 AM EST - 16 days ago

Bluejay Diagnostics Announces Completion of Commercial-Scale IL-6 Antibody Production

Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Oct 10, 2025, 5:16 PM EDT - 3 months ago

Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Oct 9, 2025, 3:15 PM EDT - 3 months ago

Bluejay Diagnostics Announces $4.5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform

Oct 9, 2025, 6:30 AM EDT - 3 months ago

Bluejay Diagnostics and SanyoSeiko Expand Strategic Partnership to Advance Commercialization of Symphony Platform

Bluejay Diagnostics Provides Second Quarter Business and Corporate Update

Aug 7, 2025, 6:30 PM EDT - 5 months ago

Bluejay Diagnostics Provides Second Quarter Business and Corporate Update

Bluejay Diagnostics Provides Mid-Year Business and Corporate Update

Jun 3, 2025, 4:05 PM EDT - 8 months ago

Bluejay Diagnostics Provides Mid-Year Business and Corporate Update

Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting

Apr 15, 2025, 7:00 AM EDT - 9 months ago

Bluejay Announces Abstract Accepted for Presentation at the 2025 Society of Academic Emergency Medicine (SAEM) Annual Meeting

Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds

Apr 7, 2025, 5:21 PM EDT - 10 months ago

Bluejay Diagnostics Announces Entry into Warrant Inducement Transaction for Approximately $3.7 Million in Gross Proceeds

Bluejay Diagnostics Announces Reverse Stock Split

Nov 13, 2024, 5:10 PM EST - 1 year ago

Bluejay Diagnostics Announces Reverse Stock Split

Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering

Jun 28, 2024, 11:32 AM EDT - 1 year ago

Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

Jun 26, 2024, 8:00 AM EDT - 1 year ago

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering

Jan 2, 2024, 5:58 PM EST - 2 years ago

Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering

Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering

Dec 28, 2023, 8:00 AM EST - 2 years ago

Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering

Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)

Dec 27, 2023, 9:00 AM EST - 2 years ago

Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)

Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results

Nov 9, 2023, 4:05 PM EST - 2 years ago

Bluejay Diagnostics, Inc. Reports Third Quarter 2023 Financial Results

Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Aug 25, 2023, 8:00 AM EDT - 2 years ago

Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results

Aug 16, 2023, 7:00 AM EDT - 2 years ago

Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial Results

Bluejay Diagnostics Updates Symphony IL-6 Regulatory Strategy

May 19, 2023, 7:00 AM EDT - 2 years ago

Bluejay Diagnostics Updates Symphony IL-6 Regulatory Strategy

Bluejay Diagnostics Reports First Quarter 2023 Financial Results

May 10, 2023, 7:30 AM EDT - 2 years ago

Bluejay Diagnostics Reports First Quarter 2023 Financial Results

Bluejay Diagnostics Reports 2022 Financial Results

Mar 20, 2023, 4:15 PM EDT - 3 years ago

Bluejay Diagnostics Reports 2022 Financial Results

Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America

Feb 16, 2023, 8:00 AM EST - 3 years ago

Bluejay Diagnostics Signs Collaboration Agreement with Blood Centers of America

Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results

Nov 9, 2022, 8:00 AM EST - 3 years ago

Bluejay Diagnostics, Inc. Reports Third Quarter 2022 Financial Results

Bluejay Diagnostics (NASDAQ:BJDX), BioSig Technologies (NASDAQ:BSGM) – Sharps Technology And 2 Other Stocks Under $2 Insiders Are Aggressively Buying

Sep 8, 2022, 9:33 AM EDT - 3 years ago

Bluejay Diagnostics (NASDAQ:BJDX), BioSig Technologies (NASDAQ:BSGM) – Sharps Technology And 2 Other Stocks Under $2 Insiders Are Aggressively Buying

STSS

Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 30, 2022, 4:05 PM EDT - 3 years ago

Bluejay Diagnostics, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Bluejay Diagnostics, Inc. to Host Key Opinion Leader Event on IL-6 Testing in Critical Care Settings: The Emerging Use of Biomarkers in Contemporary Management of COVID-19/Respiratory Failure

Aug 16, 2022, 7:30 AM EDT - 3 years ago

Bluejay Diagnostics, Inc. to Host Key Opinion Leader Event on IL-6 Testing in Critical Care Settings: The Emerging Use of Biomarkers in Contemporary Management of COVID-19/Respiratory Failure

Positive Clinical Results for Bluejay's Symphony IL-6 Test Presented at AACC 2022

Jul 27, 2022, 7:30 AM EDT - 3 years ago

Positive Clinical Results for Bluejay's Symphony IL-6 Test Presented at AACC 2022

Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results

Jul 26, 2022, 4:30 PM EDT - 3 years ago

Bluejay Diagnostics, Inc. Reports Second Quarter 2022 Financial Results

Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test

Jul 6, 2022, 7:30 AM EDT - 3 years ago

Bluejay Completes Planned Clinical Studies for Symphony IL-6 Test

Why Bluejay Diagnostics Shares Are Surging Higher Today

Jun 9, 2022, 10:19 AM EDT - 3 years ago

Why Bluejay Diagnostics Shares Are Surging Higher Today

Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results

Apr 20, 2022, 4:10 PM EDT - 4 years ago

Bluejay Diagnostics, Inc. Reports First Quarter 2022 Financial Results

Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance

Mar 28, 2022, 7:00 AM EDT - 4 years ago

Bluejay Diagnostics Appoints Edwin Rule as Vice President, Regulatory, Quality and Compliance

Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer

Mar 24, 2022, 7:00 AM EDT - 4 years ago

Bluejay Diagnostics Appoints Kenneth Fisher as Chief Financial Officer

Bluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Mar 10, 2022, 7:00 AM EST - 4 years ago

Bluejay Diagnostics, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA

Jan 31, 2022, 7:00 AM EST - 4 years ago

Bluejay Diagnostics, Inc. Announces its Pre-Submission Filing Package for the Symphony IL-6 Test is with the FDA

Bluejay Diagnostics, Inc. Completes 90 Subjects in Multicenter Clinical Study Addressing Rapid IL-6 Test for COVID-19 Patients in Critical Care

Jan 13, 2022, 11:29 AM EST - 4 years ago

Bluejay Diagnostics, Inc. Completes 90 Subjects in Multicenter Clinical Study Addressing Rapid IL-6 Test for COVID-19 Patients in Critical Care

Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor

Jan 5, 2022, 8:15 AM EST - 4 years ago

Bluejay Diagnostics, Inc. Appoints Mark Feinberg, M.D. as Chief Medical Advisor

Bluejay Diagnostics, Inc. Reports Third Quarter 2021 Financial Results

Dec 16, 2021, 9:11 AM EST - 4 years ago

Bluejay Diagnostics, Inc. Reports Third Quarter 2021 Financial Results

Bluejay Diagnostics, Inc. Announces Pricing of Upsized $21.6 Million Initial Public Offering

Nov 10, 2021, 8:15 AM EST - 4 years ago

Bluejay Diagnostics, Inc. Announces Pricing of Upsized $21.6 Million Initial Public Offering

Mike_Rotsch
Mike_Rotsch Jan. 13 at 3:02 PM
$BJDX It's time.
0 · Reply
StockDocOne
StockDocOne Jan. 13 at 2:04 AM
$BJDX
0 · Reply
GeoArafin
GeoArafin Jan. 9 at 4:57 PM
$BJDX
0 · Reply
rombrento
rombrento Jan. 9 at 12:15 PM
$BJDX
0 · Reply
HabibiMeaux
HabibiMeaux Jan. 7 at 4:53 PM
$BJDX I come back to this ticket every couple weeks to check in on it and unless they pull some magic I can see it getting delisted. Very likely they’ll do a reverse split to comply with the price requirement but that can only work for so long
0 · Reply
JohnTrack
JohnTrack Dec. 30 at 8:33 PM
$BJDX short card https://www.rapidticker.com/news/bjdx-sec-filing-16224a
0 · Reply
JohnTrack
JohnTrack Dec. 29 at 2:59 PM
$BJDX watching if shorts cover...
0 · Reply
AllandaleCapital
AllandaleCapital Dec. 29 at 12:59 PM
$BJDX in case anyone in curious off the news this am, live short interest is 4.08% Shares: 4.06M OS / 4.06M float Price: ~0.70 Market Cap: ~$3M Cash: ~$6M (Q3 est.) Cash Runway: ~12 months November 2023 (HC Wainwright) • 2,692,308 shares @ $1.30 • 2,692,308 warrants @ $1.30 • $3.5M raised June 2024 (Aegis) • 5,368,098 shares @ $1.63 • 16,104,294 warrants @ $1.96 (300% coverage) • $8.75M raised August 2024 — Toxic Cleanup • 435,377 warrants @ $0.00 strike exercised → 6.6M shares (L1) • No cash to company (pure dilution) April 2025 — Warrant Exercise (Aegis) • 1,085,106 warrants exercised @ $3.42 • $3.71M cash in • Same strike replacement warrants reissued October 2025 — Private Placement (Rodman & Renshaw) • 2,250,000 shares @ $2.00 • 4,500,000 warrants @ $1.75 • $4.5M raised Current Overhang: • ~4.5M warrants @ $1.75 (main overhang) • 1.08M warrants @ $3.42 (exercised/reissued) • 287k warrants @ $16.30 (irrelevant at current levels) • Legacy high-strike warrants ($520, $2,896, etc.) = irrelevant
0 · Reply
JohnTrack
JohnTrack Dec. 29 at 12:30 PM
$BJDX Completion of Commercial-Scale IL-6 Antibody Produ
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee Dec. 29 at 12:16 PM
$BJDX Bluejay Diagnostics Completes Commercial-Scale Production Of Polyclonal And Monoclonal Antibodies Targeting Interleukin-6, Biomarker Relevant To Inflammatory And Critical-Care Applications
0 · Reply
DARKP00L
DARKP00L Dec. 29 at 12:15 PM
$BJDX 07:07 on Dec. 29 2025 Bluejay Diagnostics Completes Commercial-Scale Production Of Polyclonal And Monoclonal Antibodies Targeting Interleukin-6, Biomarker Relevant To Inflammatory And Critical-Care Applications #tradeideas
0 · Reply
Love_To_Learn
Love_To_Learn Dec. 29 at 12:08 PM
$BJDX need u soonish
0 · Reply
InterestInc
InterestInc Dec. 25 at 8:07 AM
$BJDX The valuation debate now centers on reliability of delivery, as investors weigh durability over pace. Shortfalls would likely reprice expectations quickly.
0 · Reply
Hedgieguy75
Hedgieguy75 Dec. 23 at 6:21 PM
$BJDX warrants at $1.75 Boston, MA not mainland China Easy down here Recycled my long at $1 and now have .76 avg $OPTK and $SIDU degens Have a 👀
0 · Reply
king_gook
king_gook Dec. 22 at 5:43 PM
$BJDX she is bleeding dry
0 · Reply
MachoNacho22
MachoNacho22 Dec. 19 at 4:46 PM
$BJDX do people following this name believe in the product / IP?
0 · Reply
obeysplinkz
obeysplinkz Dec. 16 at 3:49 AM
$IVP I hope this keeps going up but hey thank god they added shorting on Robinhood now I can get my get back on $ELAB $HOLO $BJDX $FAMI shorting damn near pays out every time on those tickers now Robinhood platform can get in on some of that downward action 💯
0 · Reply
Hedgieguy75
Hedgieguy75 Dec. 12 at 3:50 PM
$BJDX wake up people .. too damn quiet in here ... she's going to reach $1.75 warrant level
1 · Reply
king_gook
king_gook Dec. 10 at 11:48 PM
$BJDX how we dooooing! added today
0 · Reply
HabibiMeaux
HabibiMeaux Dec. 9 at 1:30 AM
$BJDX for what it’s worth my GTC order got canceled on its own by WeBull I’m not sure what that implies
1 · Reply
traderjon01
traderjon01 Dec. 8 at 9:36 PM
$BJDX should move big soon ..
0 · Reply
Buyitall2024
Buyitall2024 Dec. 8 at 7:43 PM
$BJDX $BLUEJAY Diagnostics Inc is bluejay diagnostics and bluejay therapeutics same ?
0 · Reply